Sarpogrelate hydrochloride sustained release preparation

Abstract

The invention belongs to the field of pharmaceutical preparations and discloses a sarpogrelate hydrochloride sustained release preparation. The sustained release preparation consists of sarpogrelate hydrochloride, a polyvinyl acetate povidone mixture and other auxiliary materials.

Description

technical field [0001] The invention relates to the field of pharmaceutical preparations. Background technique [0002] Sarpogrelate Hydrochloride (Sarpogrelate Hydrochloride), molecular formula: C 24 h 31 NO 6 HCl, with a molecular weight of 465.97, is a 5-HT receptor blocker developed by Mitsubishi Corporation of Japan. Its pharmacological effects include the following aspects: it has specific antagonistic effect on the 5-HT2 receptor of platelets and vascular smooth muscle; it inhibits platelet aggregation Effect; Antithrombotic effect; Inhibition of vasoconstriction; Improvement of microcirculation. [0003] Currently the only product on the market is sargrelate hydrochloride tablets, the trade name is Anbu Leke, and the specification is 100mg. It is clinically used to improve ischemic symptoms such as ulcer pain and cold sensation caused by chronic arterial occlusive disease. Usage and dosage: Adults take 100mg three times a day, orally after meals, but the dosage s...

AI Technical Summary

Problems solved by technology

[0006] 1) The in vitro release shows that the drug release reaches more than 80% after 30 minutes, and the emptying time of the stomach is about 2 hours. Therefore, most of the drugs are released in the stomach, and the local concentration is high, so it is easy to cause digestive tract irritation , produce nausea, heartburn, gastrointestinal bleeding and other adverse reactions;

[0007] 2) Sagrelate Hydrochloride Tablets need to be taken 3 times a day, which is inconvenient for patients and poor compliance

Images